• Acute and chronic treatment for hepatic encephalopathy acquired from Mallinckrodt Pharmaceuticals in September 2024
• Extended pre-clinical, clinical and IP package includes FDA and EMA orphan drug and FDA fast track designations
February 11, 2025
